Savara (SVRA) Corporate presentation summary

Disease burden and treatment gap

• Autoimmune PAP is driven by GM-CSF autoantibodies that impair alveolar macrophage function and surfactant clearance, reducing oxygen delivery and potentially progressing to respiratory failure.

• Symptoms include progressive breathlessness, fatigue, reduced exercise tolerance and cough; serious infections occur in 5–13% of patients and account for 18–20% of deaths.

• Whole lung lavage is an invasive, hospital-based procedure that does not correct the underlying disease mechanism and may need repetition; long-term effects of repeated procedures are unknown.

• Patients averaged 3.5x the comorbidity burden and 167% more outpatient visits, 505% more inpatient visits and 245% more ER visits than matched controls.

• Diagnosis averaged 12 months after symptom onset to first physician visit, then 18 months from first visit to diagnosis; aPAP ClearPath testing aims to reduce testing barriers.

MOLBREEVI and IMPALA-2 results

• IMPALA-2's primary endpoint, change from baseline in DLCO at Week 24, favored MOLBREEVI over placebo (LSM difference 6.00; p=0.0007); the Week 48 difference was 6.90 (p=0.0008).

• SGRQ Total Score improved versus placebo at Week 24 (LSM difference −6.59; p=0.0072); the Week 48 difference was −4.87 (p=0.1046).

• SGRQ Activity Score favored MOLBREEVI at Week 24 (difference −7.81; nominal p=0.0149); exercise capacity favored treatment at Week 48 (difference 0.55 peak METs; nominal p=0.0234).

• Ground-glass opacity score improved versus placebo at Week 24 (post-hoc p=0.0004); rescue whole lung lavage was used by 7.4% of MOLBREEVI and 13.3% of placebo patients over 48 weeks.

• Treatment discontinuation was 3%; none of the MOLBREEVI discontinuations were attributed to drug-related adverse events, and all double-blind completers entered the open-label period.

Longer-term and real-world evidence

• Open-label follow-up showed Week 96 DLCO change of +14.7 in patients on MOLBREEVI throughout and +8.8 after placebo-to-MOLBREEVI crossover; retention was 94%.

• In a five-patient access case series, all patients responded; reported outcomes included improved lung function and imaging, reduced symptoms, and no WLL after more than one year on treatment.

• IMPALA and IMPALA-2 results were published in the New England Journal of Medicine, online in 2020 and 2025, respectively.